Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic lupus erythematosus.

Jessica J Manson1, Anisur Rahman

  • 1Centre for Rheumatology Research, Windeyer Building, University College London,46 Cleveland Street, London W1T 4JF, UK. j.manson@ucl.ac.uk

Orphanet Journal of Rare Diseases
|May 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful survival after severe aluminum phosphide poisoning complicated by cardiogenic shock, atrial fibrillation and severe metabolic acidosis: a case report.

Journal of medical case reports·2026
Same author

Publisher Correction: TLR7 in systemic lupus erythematosus: genetics and emerging therapies.

Nature reviews. Rheumatology·2026
Same author

TLR7 in systemic lupus erythematosus: genetics and emerging therapies.

Nature reviews. Rheumatology·2026
Same author

Baricitinib and ruxolitinib use through the UK HLH Network.

The Lancet. Rheumatology·2026
Same author

Effects and costs of a group-based educational intervention to reduce opioid use in people with chronic pain: I-WOTCH RCT.

Health technology assessment (Winchester, England)·2026
Same author

Controlling cardiovascular risk factors reduces progression of atherosclerosis in a multiethnic cohort of patients with lupus.

Lupus science & medicine·2026
Same journal

A lifespan pooled analysis of 832 cases: characterizing the lifespan profile of clinical presentations and comorbidities in congenital pulmonary airway malformation.

Orphanet journal of rare diseases·2026
Same journal

Mortality trends and socioeconomic inequalities in sickle cell disease in Colombia, 2012-2023: a population-based study.

Orphanet journal of rare diseases·2026
Same journal

Mitochondrial stress markers associate with phenotypic variability in Fabry disease.

Orphanet journal of rare diseases·2026
Same journal

Preclinical modeling of Loeys-Dietz syndrome: insights into mechanisms and therapy.

Orphanet journal of rare diseases·2026
Same journal

Fatigue and pain in children with multiple osteochondromas: a cross-sectional study.

Orphanet journal of rare diseases·2026
Same journal

Health service access and delivery for people living with rare disorders: a scoping review.

Orphanet journal of rare diseases·2026
See all related articles

Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organs, characterized by autoantibodies. Treatment strategies aim to manage acute flares, prevent future ones, and control daily symptoms for improved patient outcomes.

Area of Science:

  • Immunology
  • Rheumatology
  • Internal Medicine

Background:

  • Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease.
  • Characterized by autoantibodies against nuclear antigens.
  • Affects multiple organ systems with diverse clinical presentations.

Purpose of the Study:

  • To provide a comprehensive overview of Systemic Lupus Erythematosus.
  • To highlight the disease's heterogeneity, pathogenesis, and clinical manifestations.
  • To outline current treatment approaches and their impact on prognosis.

Main Methods:

  • Literature review of SLE pathogenesis, clinical features, and treatment modalities.
  • Analysis of prevalence, risk factors, and diagnostic criteria.
  • Summary of therapeutic strategies including pharmacologic interventions.

Related Experiment Videos

Main Results:

  • SLE affects approximately 1 in 1000 individuals, predominantly females (10:1 ratio).
  • Common symptoms include rash, arthritis, and fatigue; severe cases involve nephritis, neurological issues, anemia, and thrombocytopenia.
  • Over 90% of patients have positive anti-nuclear antibodies (ANA) at titers ≥ 1:80.

Conclusions:

  • SLE management requires a multi-faceted approach targeting acute, chronic, and debilitating symptoms.
  • Treatment ranges from hydroxychloroquine for mild cases to corticosteroids, immunosuppressants, and anti-CD20 antibodies for severe or refractory disease.
  • Despite treatment advancements, SLE significantly impacts patient morbidity and mortality.